Company
Spark Biomedical
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
3
510(k), De Novo and PMA
Device trials
12
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$16.2M
1 Form D offering, 2023 to 2023
Equity
$16.2M
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $16.2M raised of $21.8M sought, first sale Mar 7, 2023, 127 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Mar 7, 2023 | Equity | $16.2M | $21.8M | 127 | Rule 506(b) | Form D ↗May 12, 2023 |
Company details
From the company's latest Form D.
- Legal name
- Spark Biomedical Inc.
- Headquarters
- Dallas, Texas
- Incorporated
- Delaware in 2023
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1975271 ↗
Executives, directors and promoters
As listed on the latest Form D.
5 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
- Sparrow Ascent510(k)
K251246 · Decided Aug 25, 2025 · 125 days after receipt
Device type: Percutaneous Nerve Stimulator For Opioid Withdrawal (PZR) · Neurology & Neurosurgery
- Sparrow Ascent510(k)
K230796 · Decided Jun 20, 2023 · 90 days after receipt
Device type: Percutaneous Nerve Stimulator For Opioid Withdrawal (PZR) · Neurology & Neurosurgery
- Sparrow Therapy System510(k)
K201873 · Decided Jan 2, 2021 · 179 days after receipt
Device type: Percutaneous Nerve Stimulator For Opioid Withdrawal (PZR) · Neurology & Neurosurgery
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT07326722 · 80 participants (planned) · Start Mar 6, 2026 · Primary completion Aug 31, 2027
Device: Sparrow Link; Sparrow Link (Sham) · For: Heavy Menstrual Bleeding
Sites: Boston, Massachusetts
- tAN for First RespondersCompleted
NCT07109349 · 23 participants · Start Sep 10, 2025 · Primary completion Aug 6, 2026
Device: Sparrow Link · For: Mental Fatigue; Mental Stress
Sites: Dallas, Texas
- tAN for Substance Use DisorderRecruiting
NCT07281261 · 20 participants (planned) · Start Jan 28, 2026 · Primary completion Aug 31, 2027
Device: Sparrow Ascent; Sparrow Ascent (Sham) · For: Alcohol Use Disorder; Alcohol Abuse; Substance Use Disorders and 1 more
Sites: Houston, Texas
9 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Sparrow Ascent Patient Controller, REF's: 11-110-K, 11-310-K, 11-320-K, 11-321-K, 11-310-K-28, 11-320-K-28, 11-321-K-28Open, Classified
Z-2287-2025 · Started Jul 2, 2025 · Posted by FDA Aug 11, 2025
Reason given: Due to manufacturing issue, neurostimulator device may experience "cable disconnect" error message and interruption to stimulation output.
Cause as FDA categorized it: Process control · Device type: Percutaneous Nerve Stimulator For Opioid Withdrawal (PZR)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.